INSIGHTS ON DRUG DEVELOPMENT

• Integrated QC As A Development Strategy: Reducing Late-Stage Analytical Risk

  Learn how early QC integration, proactive analytical risk management, and cross-functional collaboration can improve validation readiness, reduce development surprises, strengthen release testing predictability, and help protect critical clinical manufacturing timelines.

• Benchmarking Filtration Performance Of TFF Cassettes

  Optimize your protein purification workflow with tangential flow filtration by comparing membrane performance and exploring how protein concentration impacts flux and MWCO selection in lab-scale systems.

• Functional Characterization Of 3D Assembled Neurospheres

  Neural organoids and 3D spheroids offer advanced platforms for brain research and drug discovery. Discover how creating 3D neurospheres from iPSC-derived neurons and astrocytes aids in compound profiling and toxicity testing.

• Ophthalmic Drug Delivery: Meeting Modern Challenges With A Next Generation Solution

  Ophthalmic injectable packaging demands early strategic attention. Learn how silicone oil contamination, particulate limits, and dosing accuracy challenges can derail development programs and what it takes to stay compliant.

• An Integrated Analytical Approach To Lipase Risk Management In Biologics Development

  9/8/2026

  Conventional HCP testing cannot confirm whether residual lipases remain enzymatically active. Here, the authors examine why functional activity data are essential for managing polysorbate-related stability risk in biologics development.

• Spray Dried Biologics For Pulmonary Dosage Forms

  5/15/2026

  Spray drying creates stable inhalable biologic powders with controlled particle size, enabling effective lung delivery, improved stability, and scalable production for respiratory and systemic therapies.

• ADC Development Grows More Complex — SPR Insights Bring Clarity

  4/14/2026

  Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

• NGS In GMP Manufacturing: Reducing Risk, Increasing Return

  1/29/2026

  Global regulators now recognize NGS as a rigorous, GMP‑ready tool for viral safety, driving a shift toward scalable quality strategies. Learn why NGS is becoming central to modern manufacturing.

• Leveraging Early Insights To Accelerate The Oral Drug Development Cycle

  8/31/2026

  Consider how the following early development insights can help you navigate complex oral drug development and move your program forward with greater confidence.